现代药的最新2025-2026年COVID疫苗在高危群体中将抗体增加8倍,并在美国和几个国家得到批准。 Moderna's updated 2025-2026 COVID vaccine boosts antibodies 8-fold in high-risk groups and is approved in the U.S. and several countries.

Moderna 更新的 2025-2026 年 Spikevax COVID-19 疫苗针对 LP.8.1 变体和相关毒株，显示 12 至 64 岁有基础疾病的临床试验参与者和 65 岁及以上成年人的中和抗体增加了 8 倍。 Moderna's updated 2025-2026 Spikevax COVID-19 vaccine, targeting the LP.8.1 variant and related strains, shows an 8-fold increase in neutralizing antibodies in clinical trial participants aged 12 to 64 with underlying conditions and adults 65 and older. 初步阶段4试验数据证实,免疫反应有力,安全情况与以前版本一致,没有新的不利事件。 Preliminary Phase 4 trial data confirms strong immune responses and a safety profile consistent with prior versions, with no new adverse events. 在美国,对高危人群和包括加拿大、欧洲、日本、墨西哥和瑞士在内的多个国家,该疫苗得到核准。 The vaccine is approved in the U.S. for high-risk individuals and in multiple countries including Canada, Europe, Japan, Mexico, and Switzerland.